VASCAMY

Vascular and Aymloid Predictors of Neurodegeneration and Cognitive Decline in Nondemented Subjects

 Coordinatore LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN 

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Ms.
Nome: Dorothee
Cognome: Hasebrink
Email: send email
Telefono: +49 89 2180 3605
Fax: +49 89 2180 2985

 Nazionalità Coordinatore Germany [DE]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-CIG
 Funding Scheme MC-CIG
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2017-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Ms.
Nome: Dorothee
Cognome: Hasebrink
Email: send email
Telefono: +49 89 2180 3605
Fax: +49 89 2180 2985

DE (MUENCHEN) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

florbetaben    executive    brain    episodic    vascular    years    amyloid    predict    age    pet    clinical    function    white    stage    subjects    decline    ad    dementia    cerebrovascular    memory    szlig    pathology    network    cognitive    dti    occurs    mri    networks    persons    degeneration    disease   

 Obiettivo del progetto (Objective)

'Alzheimer’s disease (AD) is the most frequent cause of dementia that affects one in 14 persons over the age 65 years and one in six persons over the age of 80 years. Increased deposition of the protein beta-amyloid (Aß) is a core brain pathology of AD that occurs years before the onset of clinical symptoms of dementia. Together with Aß, cerebrovascular disease, visible as on a MR image as white matter abnormalities, frequently co-occurs. A major question is whether Aß and cerebrovascular disease independently from each other predict disease progression and cognitive decline. The overall goal of the combined amyloid PET and MRI study is to assess how Aß pathology and vascular white matter damage contribute to cognitive decline through particular neuronal networks at an early stage of the disease. To this end, we will assess in a prospective 4-year longitudinal neuroimaging study 80 subjects with mild cognitive impairment (MCI) of episodic memory or executive function and 50 elderly cognitively healthy subjects (HC). Brain changes in association with Aß (florbetaben PET) and white matter degeneration (MRI, DTI) will be assessed in two major networks 1) temporo-parietal network that is typically associated with episodic memory, and 2) a subcortical-prefrontal network that is typically associated with executive function. Specifically, florbetaben PET binding and volumes of WMH and lacunes at baseline will be tested as predictors of fiber tract degeneration (DTI) and grey matter atrophy of those networks and cognitive decline during annual follow-up assessments. We expect that the results of this study will provide us with a clear understanding of the joint effects of the Aß and vascular white matter pathology on brain degeneration to predict cognitive decline during an early disease stage. This will help to identify subjects at risk of developing eventually dementia and will provide endpoints for clinical trials of disease modifying drugs to prevent dementia.'

Altri progetti dello stesso programma (FP7-PEOPLE)

TUBEREMODELLING (2012)

"Tubular organ remodelling during development, homeostasis and disease"

Read More  

ILSES (2013)

Metal nanoparticle interactions with bioorganic molecules and their applications in biosensing

Read More  

TRANSCLCONDREG (2013)

Arylpyrrole-based Transmembrane Transporters for Induced Chloride Regulation in Cystic Fibrosis Epithelial Cells

Read More